Take a peek at what’s coming out of the first day and a half of the J.P. Morgan Healthcare Conference:
GenomeWeb recapped day one of the conference including positive highlights on Genomic Health and a few of Myriad’s 2013 setbacks.
Reuters reported on Regeneron’s $400 million in U.S. sales of Eylea for the fourth quarter of 2013.
BMS will piggyback its hepatitis C experimental drug with Gilead’s approved pill, according to Bloomberg News.
Adam Feuerstein published some midday random thoughts on day one of the conference, including mentions of Celgene and Seattle Genetics.
The Pink Sheet reported on chats with the CEOs of Elcelyx Therapeutics and Arecor, and news from Juno Therapeutics and Galena Biopharma.
Scrip reported that there were few empty seats for the Seattle Genetics update on the company’s antibody-drug conjugate pipeline.
Doug Braunstein, CFO of J.P. Morgan, noted the record 9,200 conference attendees compared to less than 100 attendees at the first event back in 1983, according to an article by Medical Device Daily.
Since the conference opened on Monday morning, there have been nearly 4,000 tweets using #jpm14, with over 2,700 tweets since noon on Monday.
Today’s most retweeted tweet comes from Sarah Kliff of the Washington Post:
Second place goes to Kevin Davies, author of “The $1,000 Genome” and founding editor of Nature Genetics:
The top 5 companies in $Cashtag mentions since noon yesterday are Gilead, Arena, Bristol-Myers Squibb, Biogen and Vertex. All are seeing bumps in their stock price as of 10:45 this morning.